The experimental HSPN rat model was established by using the co-administration of bovine serum albumin (BSA), lipopolysaccharide (LPS), and carbon tetrachloride (CCl₄). Blood and proteinuria were detected in each group of rats. IgA deposition was detected by immunofluorescence, pathological changes of glomeruli and renal tubules under light microscope and changes of basement membrane, podocytes and mesangial area under electron microscope were observed, and whether to establish an effective HSPN rat model was comprehensively evaluated. Then the experimental rats were given different concentrations of JHXZ by gavage for 4 weeks, and western medicine piperazine ferulate tablets were used as positive control to observe the effects of JHXZ intervention on the pathological changes of renal tissue and the contents of urinary red blood cells and urinary protein in experimental rats. Finally, by measuring the protein expressions and mRNA levels of Wnt3a, Wnt4, Wnt9b, GSK-3β, β-catenin, TCF-4, MMP-7 and E-cadherin in renal tissues and mesangial cells, the correlation of Wnt/β-catenin signaling pathway in the pathogenesis of HSPN and its role in the treatment of HSPN diseases were evaluated.The results of the study showed that the results of urine testing, immunofluorescence, light microscope and electron microscope showed that there were increased red blood cells and proteins in urine, IgA deposition and mesangial proliferation, basement membrane proliferation, abnormal changes in podocyte morphology and quantity in all groups except the normal group, especially in the model group, which indicated that the HSPN rat model was successfully prepared. After high-dose JHXZ treatment, the IgA deposition in kidney, the proliferation degree of mesangial area and basement membrane, and the morphology and number of podocytes in HSPN rat model are close to normal, while the red blood cells, proteins in urine and IL-2, IL-4 and IFN-γ in blood are obviously decreased, and the effect is better with the increase of dose. The results of PCR and WB in vivo and in vitro were highly consistent. According to PCR and WB detection, it was found that high-dose JHXZ treatment could significantly reduce the gene and protein expression levels of Wnt3a, Wnt4, Wnt9b, GSK-3β, β-catenin, TCF-4, MMP-7 in model rats, and maintain the high expression of E-cadherin gene and protein. In addition, piperazine ferulate tablets are the first-line therapeutic drugs for HSPN, which was used as a positive control in this experiment. Our results show that compared with rats treated with piperazine ferulate tablets, the high-dose JHXZ group has better effects on improving the pathological changes of renal tissue, reducing urine red blood cells and reducing the expression of GSK-3β gene and protein. Our experiments proved that the activation of Wnt/β-catenin is involved in the pathogenesis of HSPN. JHXZ can regulate mesangial cells through Wnt/β-catenin to protect kidney.

Niqin Xiao, Caixia Zhao, Junyu Luo, Xianfeng Luo, Qiqi Chang, Jiao Xiong, Min Wang, Xi Li, Min Zhao, Zhifeng Wang, Ping He. Mechanism of action of Jinghua Xiaozi Mixture in the treatment of Henoch Schonlein Purpura Nephritis revealed by Wnt/β-Catenin signaling pathway. Frontiers in Medical Science Research (2024), Vol. 6, Issue 8: 1-16. https://doi.org/10.25236/FMSR.2024.060801.

[1] Sestan M, Jelusic M. Diagnostic and Management Strategies of IgA Vasculitis Nephritis/Henoch-Schönlein Purpura Nephritis in Pediatric Patients: Current Perspectives. Pediatric Health Med Ther. 2023; 14:89-98.

[2] Sapina M, Frkovic M, Sestan M, Srsen S, Ovuka A, Batnozic Varga M, et al. Geospatial clustering of childhood IgA vasculitis and IgA vasculitis-associated nephritis. Ann Rheum Dis. 2021; 80(5):610-6.

[3] Jelusic M, Sestan M, Cimaz R, Ozen S. Different histological classifications for Henoch-Schönlein purpura nephritis: which one should be used? Pediatr Rheumatol Online J. 2019; 17(1):10.

[4] Luo X, Tan J, Wan D, Chen J, Hu Y. Predictability of the Oxford classification of IgA nephropathy in Henoch-Schonlein purpura nephritis. Int Urol Nephrol. 2022; 54(1):99-109.

[5] Chen JY, Mao JH. Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management. World J Pediatr. 2015; 11(1):29-34.

[6] Zhou JH, Huang AX, Liu TL, Kuang YJ. A clinico-pathological study comparing Henoch-Schonlein purpura nephritis with IgA nephropathy in children. Zhonghua Er Ke Za Zhi. 2003; 41(11):808-12.

[7] Kronbichler A, Bajema I, Geetha D, Säemann M. Novel aspects in the pathophysiology and diagnosis of glomerular diseases. Ann Rheum Dis. 2023; 82(5):585-93. 

[8] Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-80.

[9] Naija O, Bouzaraa J, Goucha-Louzir R, Lakhoua MR. [Predictive factors of severe Henoch-Schonlein nephritis in children: report of 34 cases]. Tunis Med. 2012; 90(12):878-81.

[10] He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol. 2009; 20(4):765-76.

[11] Zang T, Zhuang L, Zhang Z, Xin D, Guo Y. Expression of beta-catenin in renal cell carcinoma. Chin Med J (Engl). 2001; 114(2):152-4.

[12] He X. Cilia put a brake on Wnt signalling. Nat Cell Biol. 2008; 10(1):11-3.

[13] Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis. Kidney Int. 2011; 80(1):79-87.

[14] Kawasaki Y, Suzuki J, Sakai N, Nemoto K, Nozawa R, Suzuki S, et al. Clinical and pathological features of children with Henoch-Schoenlein purpura nephritis: risk factors associated with poor prognosis. Clin Nephrol. 2003; 60(3):153-60.

[15] Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006; 281(32):22429-33.

[16] Boivin FJ, Sarin S, Lim J, Javidan A, Svajger B, Khalili H, et al. Stromally expressed β-catenin modulates Wnt9b signaling in the ureteric epithelium. PLoS One. 2015; 10(3):e0120347.

[17] Wang L, Chi YF, Yuan ZT, Zhou WC, Yin PH, Zhang XM, et al. Astragaloside IV inhibits the up-regulation of Wnt/β-catenin signaling in rats with unilateral ureteral obstruction. Cell Physiol Biochem. 2014; 33(5):1316-28.

[18] Leung AKC, Barankin B, Leong KF. Henoch-Schönlein Purpura in Children: An Updated Review. Curr Pediatr Rev. 2020; 16(4):265-76.

[19] Maritati F, Canzian A, Fenaroli P, Vaglio A. Adult-onset IgA vasculitis (Henoch-Schönlein): Update on therapy. Presse Med. 2020; 49(3):104035.

[20] Pillebout E, Sunderkötter C. IgA vasculitis. Semin Immunopathol. 2021; 43(5):729-38.

[21] Reamy BV, Servey JT, Williams PM. Henoch-Schönlein Purpura (IgA Vasculitis): Rapid Evidence Review. Am Fam Physician. 2020; 102(4):229-33.

[22] Davin JC, Coppo R. Henoch-Schönlein purpura nephritis in children. Nat Rev Nephrol. 2014; 10(10):563-73.

[23] Li YY, Li CR, Wang GB, Yang J, Zu Y. Investigation of the change in CD4⁺ T cell subset in children with Henoch-Schonlein purpura. Rheumatol Int. 2012; 32(12):3785-92.

[24] Reichert P, Reinhardt RL, Ingulli E, Jenkins MK. Cutting edge: in vivo identification of TCR redistribution and polarized IL-2 production by naive CD4 T cells. J Immunol. 2001; 166(7):4278-81.

[25] Wu JJ, Zhu YT, Hu YM. Mechanism of feedback regulation of neutrophil inflammation in Henoch-Schönlein purpura. Eur Rev Med Pharmacol Sci. 2016; 20(20):4277-85.

[26] Li Y, Sui X, Zhu H, Xu Y, Huang L, Xu Y, et al. Histopathological and immunological changes during the acute and recovery phase in Henoch-Schönlein purpura rabbit model. Arch Dermatol Res. 2017; 309(1):21-30.

[27] Li Xiaoping, Cao Yu. The role of inflammation in the pathogenesis of anaphylactoid purpura nephritis. Internal Medicine. 2020; 15 (03): 312-4.

[28] Xu H, Li W, Fu H, Jiang G. Interferon-gamma gene polymorphism +874 (a/t) in Chinese children with Henoch-Schonlein purpura. Iran J Allergy Asthma Immunol. 2014; 13(3):184-9.

[29] Bai Tao-min, Wang Jie-ying, Li Rui, Liu Na, Zhang Xiaoyan. The clinical significance of HSP plasma levels of IFN-γ, IL-6, IL-17 and TGF-β1 in the evaluation of purpura nephritis in children. Journal of Hebei Medicine. 2019; 41 (14): 2182-5.

[30] Wu SH, Liao PY, Chen XQ, Yin PL, Dong L. Add-on therapy with montelukast in the treatment of Henoch-Schönlein purpura. Pediatr Int. 2014; 56(3):315-22.

[31] Su Z, Lv X, Liu Y, Zhang J, Guan J, Gai Z. Circulating midkine in children with Henoch-Schönlein purpura: Clinical implications. Int Immunopharmacol. 2016; 39:246-50.

[32] Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022; 7(1):3.

[33] Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, et al. Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021; 6(1):307.

[34] Huang P, Yan R, Zhang X, Wang L, Ke X, Qu Y. Activating Wnt/β-catenin signaling pathway for disease therapy: Challenges and opportunities. Pharmacol Ther. 2019; 196:79-90.

[35] Colozza G, Koo BK. Wnt/β-catenin signaling: Structure, assembly and endocytosis of the signalosome. Dev Growth Differ. 2021; 63(3):199-218.

[36] Lv X, Li J, Hu Y, Wang S, Yang C, Li C, et al. Overexpression of miR-27b-3p Targeting Wnt3a Regulates the Signaling Pathway of Wnt/β-Catenin and Attenuates Atrial Fibrosis in Rats with Atrial Fibrillation. Oxid Med Cell Longev. 2019; 2019:5703764.

[37] Li Xiu, Zhang Xiaocui, Zhang Hongli, Zhao Qixing, Deng Fang. Observation of correlation between Wnt/β-catenin signaling pathway and anaphylactoid purpura in children. Chinese Journal of Cell Biology. 2018; 40 (7): 1179-83.

[38] Wang Z, Li Z, Ji H. Direct targeting of β-catenin in the Wnt signaling pathway: Current progress and perspectives. Med Res Rev. 2021; 41(4):2109-29.

[39] Lv Q, Wang J, Xu C, Huang X, Ruan Z, Dai Y. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways. Mol Med. 2020; 26(1):49.

[40] Wong SHM, Fang CM, Chuah LH, Leong CO, Ngai SC. E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 2018; 121:11-22.

[41] He W, Tan RJ, Li Y, Wang D, Nie J, Hou FF, et al. Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/β-catenin activity in CKD. J Am Soc Nephrol. 2012; 23(2):294-304.

[42] Liu Z, Tan RJ, Liu Y. The Many Faces of Matrix Metalloproteinase-7 in Kidney Diseases. Biomolecules. 2020; 10(6).